Activity hots up on aligning EMA and HTA decisions
This article was originally published in SRA
Momentum is building around efforts to identify how the European Medicines Agency and EU health technology assessment (HTA) bodies can become better aligned so as to improve how drug sponsors fare in HTAs.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.